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Background: Patient reported outcomes (PROs) are important measures in rheumatoid arthritis (RA). A register of
patients with RA from all rheumatology care providers in Malmö, Sweden, was established in 1997 and has been
continually updated. This register includes virtually all the RA patients in the area. The aim of this study was to
analyse PROs in surveys of this population conducted between 1997 and 2009, and to assess differences in
treatment and outcome in male and female patients.
Method: In 1997, 2002, 2005 and 2009, questionnaires were sent to the RA patients in the register (n = 1016 in
1997; n = 916 in 2002; n = 1625 in 2005; n = 1700 in 2009). Response rates varied between 62 % and 74 %, and
72-74 % was women. Questionnaire data included medication and measures of disability and health related quality
of life. Data on rheumatoid factor (RF) tests were retrieved from the databases of the two clinical immunology
laboratories in the area. In order to limit the impact of changes in the case mix over time, the study was restricted
to RF positive patients. The analyses were stratified by sex.
Results: Patients reported less severe outcomes for all measures in the later surveys compared to 1997, and
patients’ global disease activity assessment and self-reported pain were further improved in 2009 compared to
2005. Treatment with biologics increased over time from 1997 (none) to 2009 (29%), with no difference between
men and women. Visual analogue scales (0-100) for patients’ global assessment of disease activity [mean 45
(95 % CI (45-47) vs. 38 (35-40)] and pain [mean 46 (44-49) vs. 38 (36-40)] decreased from 1997 to 2009, with
numerically greater improvement in male patients. The mean SF-36 physical component scores also improved, and
were higher in men than in women in all surveys.
Conclusion: Pharmacologic treatment of RA became more extensive over time, and there was improvement in all
PROs. Despite similar treatment, male patients reported better outcomes, in particular for pain and physical
function, compared to female patients. We suggest that patient reported outcomes should be reported separately
in male and female patients with RA.Background
Rheumatoid arthritis (RA) is a chronic, inflammatory
disorder, which is characterized by progressive joint dam-
age and has a major impact on physical function and
health related quality of life (HRQoL). There is evidence
indicating that the disease has become less severe during
the last decades, possibly due to better management with
more extensive treatment, or secular changes in other
factors influencing disease severity. For example, a lower* Correspondence: Korosh.Hekmat@med.lu.se
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reproduction in any medium, provided the ordisease activity and disability in 1995 compared to 1978 has
been demonstrated in Swedish patients with RA [1], and a
recent survey indicated that the incidence of total hip
arthroplasties has decreased in RA patients over time [2].
Furthermore, severe extra-articular RA manifestations such
as vasculitis have also become less frequent in recent years
[3]. On the other hand, in poor countries many patients still
have active, uncontrolled disease [4].
A patient-reported outcome (PRO) is a questionnaire
used in a clinical trial or a clinical setting, where the
responses are collected directly from the patient. A num-
ber of PROs are validated measures that are consideredl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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quantitative measures for standard rheumatology clinical
care [6]. RA is far more common in women, and sex spe-
cific factors may also influence various aspects of disease
severity, including PROs. For example, there seem to be
gender differences with worse reported HRQoL among fe-
male patients with early RA [7], and a fourfold increased
risk of work disability in women with RA compared to men
[8]. The impact of recent changes in management and
recent secular changes on such differences is unknown.
Our aim was to investigate changes over time in PROs
such as visual analogue scales (VAS) for patients’ global
assessment of disease activity and pain, disability and
HRQoL, as well as treatment in male and female patients
in a population-based sample of patients with RA.
Methods
Patients
In 1997, a register of all known patients with RA in the
city of Malmö, Sweden, was established. Inclusion was
based on a clinical diagnosis of RA by a rheumatologist and
fulfilment of the 1987 American College of Rheumatology
(ACR) criteria for RA [9].
The corresponding background population of Malmö
was 251,000 in 1997. Patients were recruited from the
rheumatology outpatient clinic of Malmö University
Hospital (as of 2010 a part of Skåne University Hospital),
which is the only hospital serving the city, and from the
four rheumatologists in private practice in Malmö [10].
The close collaboration between the university clinic and
the private practitioners and the methods for recruiting
patients to the register, which has been continuously
updated after 2002, have been described in detail previ-
ously [10,11,2].
The prevalence of RA in the area (approximately 0.5 %
among those aged 20 years and above) and the sex and
age distributions in the Malmö RA register were found
to be comparable to the RA prevalence in a study from
a population-based RA register in Oslo, Norway [12].
Subsequent surveys using the diagnostic index of primary
care centres and questionnaires sent to other physicians in
the area indicate that >90% of all patients with diagnosed
RA in the city at that time were included in the register.
All registered cases with RA were validated by review of
the case records as previously described [11,2].
Variables
In 1997, 2002, 2005 and 2009, self-administered question-
naires were sent to the patients in the Malmö RA register.
Demographics, working status, medication with dis-
ease modifying anti-rheumatic drugs (DMARDs), visual
analogue scales (VAS) for general health and pain, use of
healthcare, the Swedish version of the health assessment
questionnaire (HAQ) [13], and HRQoL as measured bythe Swedish version of the short form (SF)-36 were
assessed [14,15].
SF-36 is a generic measure of eight health dimensions
(physical functioning, physical role, bodily pain, general
health, vitality, social functioning, emotional role, mental
health) with scale from 0 to 100 (0 worst health). A reminder
was sent to patients who did not answer the questionnaire
the first time.
The study was approved by the regional research ethics
committee in Lund, Sweden. Data on rheumatoid factor
(RF) tests were retrieved from the databases of the two
clinical immunology laboratories in the area. In order to
limit the impact of changes in the case mix, in particular
regarding mild, RF negative cases, over time, in the present
comparison, only patients with at least one positive RF test
were included. The analyses were stratified by sex.
Statistical analysis
Data were analyzed with version 18.0 of the Statistical
Package for the Social Sciences (SPSS Inc., Chicago, IL).
As the questionnaire data in 1997, 2002, 2005 and 2009
included partly overlapping patient populations, no formal
statistical comparisons were made between these patient
cohorts. Too few had responded to repeated surveys to
allow meaningful longitudinal data analyses. Variables
with a normal distribution are presented as means with
95% confidence intervals (95% CI) whereas those with
a non-normal distribution are presented as medians
with interquartile ranges (IQR). As a conservative estimate
we assumed that a significant change had occurred if
the 95% CIs of a measure in 1997 and at subsequent
years of examination did not overlap. The SF-36 scores
were compared to the expected derived from norma-
tive values from the Swedish population [16] for each
individual, and mean differences from the expected
with 95 % CI were calculated for each survey. CIs not
including zero were interpreted as indicating a significant
difference from the expected.
Results
In 1997, 2002, 2005 and 2008, questionnaires were sent
to the RA patients in the register (n = 1016 in 1997; n = 916
in 2002; n = 1625 in 2005 and n = 1700 in 2009). Overall
response rates were 74 %, 66 %, 64 % and 62 %, respect-
ively. The demographics of responders with at least one
positive test for RF are shown in Table 1. There was no
major difference in disease duration and age between
the surveys (Table 1).
Temporal trends in treatment and PROs
More patients were treated with methotrexate in 2005
and 2009 compared to 1997 (Figure 1).
As expected, treatment with TNF inhibitors and other
biologics was only reported in 2002 and later. Reported
Table 1 Demographics, treatment and patient reported outcomes in four surveys of RF positive patients in the Malmö
RA population
1997 2002 2005 2009
N 668 438 517 454
Disease duration years, mean (SD) 15.0 (13.6) 16.7 (12.5) 15.8 (12.5) 17.2 (12.1)
Female sex 497 (74%) 321 (73%) 368 (71%) 331 (73%)
Age; years, mean 61.9 (14.1) 63.9 (13.6) 62.9 (14.2) 63.8 (13.4)
Current treatment proportion (95 % CI)
Corticosteroids 19% (16-22) 30% (26-35) 26 % (23-30) 31 % (27-35)
Biologic 0 16% (12-19) 23 % (19-27) 29 % (25-33)
Methotrexate 20% (17-23) 44% (40-49) 56 % (52-60) 58 % (54-63)
Patient reported outcomes mean (95% CI) unless otherwise noted
HAQ* 1.12 (0.50-1.75) 1.00 (0.50-1.62) 0.88 (0.38-1.38) 0.88 (0.38-1.5)
VAS global 44.8 (42.3-47.4) 40.0 (37.6-42.4) 41.8 (39.6-44.1) 37.6 (35.2-40.0)
VAS pain 46.3 (43.7-48.9) 41.1 (38.8-43.5) 40.8 (38.6-43.0) 38.2 (35.8-40.7)
SF-36 PCS 32.1 (31.0-33.1) 33.2 (32.2-34.4) 34.6 (33.6-35.7) 35.2 (34.0-36.4)
SF-36 MCS 45.4 (44.0-46.7) 46.7 (45.4-48.1) 47.9 (46.7-49.0) 47.1 (45.9-48.3)
* median (IQR).
PCS = Physical component score.
MCS =Mental component score.
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time from 2002 to 2009, without major differences between
male and female patients (Figure 1). In 2009, 29% of
patients of both sexes were treated with biologics. Triple
therapy with methotrexate, sulphasalazine and antimalarials
was used in <1% in 1997, 2002 and 2009. For 2005 data on
triple therapy were not available.Figure 1 Current treatment with methotrexate and biologics in RF positivPatients’ global assessment of disease activity and pain
both decreased substantially from 1997 to 2009 (Table 1).
There was a similar trend for HAQ, with the exception of
2005 and 2009, when the median HAQ score was stable
(Table 1). The mean SF-36 physical component scores were
substantially better in the later surveys (Table 1). In particu-
lar, there was improvement over time in the physical healthe rheumatoid arthritis patients in 1997, 2002. 2005 and 2009, by sex.
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body pain (Figure 2). There were similar, although more
modest, changes in the SF-36 mental component score
(Table 1) and the mental health related scores (Figure 3).
Despite these improvements, even in 2009 the scores
were significantly lower compared to the expected de-
rived from normative values from the Swedish population
(mean difference with 95% CI for Physical functioning
21.9 (19.3-24.4), Role physical 21.2 (17.0-25.5) Body pain
18.4 (16.3-20.5), General health 19.0 (16.8-21.3), Vitality
15.6 (13.1-18.1), Social functioning 13.6 (11.0-16.2), Role-
emotion 15.2 (11.1-19.2) and Mental health 7.4 (5.3-9.5)).
Sex differences in PROs
There was no major difference in age between male and
female responders in either of the surveys (Table 2). Male
patients reported better outcomes with lower point esti-
mates for VAS global, VAS pain and HAQ and higher
point estimates for SF-36 PCS and SF-36 MCS (Table 2)
in all four surveys (Table 2). In addition, the numerical
differences for all these outcomes between mean values in
2009 vs 1997 were greater for men than women, especially
for VAS pain (difference 11.5 in men vs. 7.0 in women)
and VAS global (difference 9.2 in men vs. 7.1 in women)
(Table 2). When examining SF-36 domain scales individu-
ally, a similar pattern was seen for all domains, with higher
values for male patients than for females at all time points
(Table 3). The difference between men and women in
physical functioning was consistent in all surveys, with
non-overlapping confidence intervals, and increased nu-
merically over time (Table 3). For role physical, bodily painFigure 2 SF-36 Physical health related scales in RF positive rheumato
confidence intervals.and vitality, similar increasing differences were seen
over time, with consistently higher values in men, in
particular in the latter two surveys (where the CI were
non-overlapping compared to women) (Table 3). The
difference in mental component scores was smaller with
less change over time (Table 2). In all four surveys, female
as well as male patients with RA had lower scores for all
SF-36 domains compared to the expected derived from
sex-specific population based normative values, with CIs
not overlapping zero for all differences, and numerically
greater differences for women (data not shown).
Discussion
In this study, we found that treatment with biologics and
corticosteroids increased over time, and there was im-
provement in all patient reported outcomes. Despite simi-
lar treatment, male patients reported better outcomes and
more improvement, in particular for the impact of pain,
compared to female patients.
Several previous studies have reported improved out-
comes over time in comparisons of samples of patients with
RA evaluated at different time points. Such improvements
were observed in patients’ clinical status according to dis-
ease activity [1,17], functional capacity [17-19], radiographic
scores [17,20], and other clinical measures [17]. This most
likely at least partly reflects the fact that management and
treatment of RA has become more efficient in recent years.
Several clinical trials have shown that tight control of dis-
ease activity can be achieved in many patients with early
RA by optimizing treatment with traditional DMARDs
[21,22]. Current guidelines emphasize the importance of aid arthritis patients in 1997, 2002. 2005 and 2009. Means with 95%
Figure 3 SF-36 Mental health related scales in RF positive rheumatoid arthritis patients in 1997, 2002. 2005 and 2009. Means with 95%
confidence intervals.
Hekmat et al. BMC Musculoskeletal Disorders 2014, 15:44 Page 5 of 8
http://www.biomedcentral.com/1471-2474/15/44treat to-target approach [23], with addition of TNF-
inhibitors and other biologics in refractory cases or as first
line therapy in patients with a severe prognosis [24,25].
Currently, decision making about treatment of RA in the
studied population and in other parts of Sweden is largely
based on national guidelines [25]. In Malmö, initiation of
treatment with biologics is discussed at a scheduled meet-
ing, to ensure uniform indications in clinical practice.Table 2 Demographics and patient reported outcomes in fou
population, by sex
1997 2002
WOMEN MEN WOMEN ME
N 497 171 321 11
Age 62.0 61.8 64.0 63
Mean (SD) (14.2) (13.7) (14.0) (12
HAQ 1.4 1.0 1.1 0.
Median (IQR) (0.6-2.0) (0.1-1.3) (0.6-1.8) (0.1-
VAS pain 48.3 40.4 43.2 35
(45.3-51.4) (35.3-45.6) (40.4-45.9) (31.3-
VAS global 46.4 40.5 41.6 35
(43.4-49.3) (35.5-45.5) (38.8-44.5) (31.3-
SF-36 PCS 30.8 35.6 32.3 35
(29.7-32.0) (33.5-37.7) (31.1-33.6) (33.7-
SF-36 MCS 44.8 46.9 46.5 47
(43.2-46.4) (44.4-49.4) (44.8-48.1) (45.1-
All values are means (95% CI) unless otherwise noted.
PCS = Physical component score.
MCS =Mental component score.Triple therapy with methotrexate, sulphasalazine and
antimalarials was rarely used in this cohort. The low use
of triple therapy in 2009 was similar to that observed
in 2010 in a cross sectional study from Kristiansand,
Norway [26], but lower than that reported from Jyväskylä,
Finland, where biologics were less extensively used [26].
The comparison between the cohorts from Kristiansand
and Jyväskylä suggested that good functional statusr surveys of RF positive patients in the Malmö RA
2005 2009
N WOMEN MEN WOMEN MEN
7 362 148 326 120
.6 62.8 63.2 63.8 63.7
.6) (14.8) (12.9) (13.9) (12.3)
6 1.0 0.5 1.0 0.4
1.4) (0.5-1.6) (0.0-1.0) (0.5-1.6) (0.0-1.1)
.7 43.2 34.4 41.3 28.9
40.0) (40.6-45.8) (30.2-38.5) (38.4-44.1) (24.6-33.1)
.6 43.8 36.6 39.3 31.3
39.8) (41.2-46.5) (32.3-40.8) (36.5-42.2) (27.0-35.5)
.8 33.2 38.3 33.8 39.7
38.0) (32.0-34.4) (36.3-40.3) (32.4-35.1) (37.5-41.9)
.5 47.1 50.0 46.4 49.2
49.9) (45.7-48.5) (47.9-57.1) (45.0-47.9) (46.9-51.5)
Table 3 SF-36 domain scores in four surveys of RF positive patients in the Malmö RA population, by sex
1997 2002 2005 2009
SF-36 domain WOMEN MEN WOMEN MEN WOMEN MEN WOMEN MEN
Physical functioning 43.1 52.8 46.2 53.8 47.0 60.7 49.9 61.9
(40.4-45.8) (48.2-57.4) (43.2-49.2) (48.6-59.0) (44.2-49.9) (56.1-65.3) (46.8-52.9) (56.6-67.2)
Role physical 33.6 45.7 36.7 47.7 42.6 58.5 43.5 62.2
(29.1-38.1) (37.6-53.8) (31.8-41.6) (38.7-55.7) (38.1-47.2) (51.1-65.8) (38.6-48.3) (54.4-70.1)
Body pain 39.6 46.1 44.1 49.0 46.4 53.9 46.2 58.3
(37.4-41.9) (41.9-50.3) (41.7-46.5) (45.2-52.9) (44.2-48.6) (50.4-57.5) (43.8-48.6) (53.8-62.7)
General health 42.7 48.0 45.4 50.6 46.8 53.1 47.9 54.0
(40.4-45.0) (44.0-52.0) (42.9-47.9) (46.4-54.8) (44.5-49.1) (49.3-56.9) (45.4-50.5) (49.7-58.3)
Vitality 44.5 48.5 45.7 50.4 48.2 56.2 47.2 56.8
(41.9-47.0) (44.1-53.0) (43.0-48.4) (45.7-55.2) (45.7-50.7) (52.2-60.3) (44.4-49.9) (51.7-61.9)
Social functioning 66.1 71.9 68.9 70.4 70.6 80.2 69.9 77.4
(63.1-69.2) (67.0-76.9) (65.8-72.1) (65.2-75.6) (67.6-73.5) (76.4-84.1) (66.8-73.0) (72.5-82.3)
Role-emotional 51.0 61.6 57.7 61.9 59.8 70.3 59.9 72.5
(45.9-56.1) (53.1-70.1) (52.4-63.0) (53.7-70.1) (55.1-64.5) (63.3-77.3) (55.0-64.7) (65.0-79.9)
Mental health 66.8 76.0 69.7 77.6 70.9 72.9 70.1 69.9
(64.3-62.3) (71.9-80.0) (67.0-72.3) (74.1-81.0) (68.6-73.3) (68.8-77.0) (67.7-72.6) (65.8-74.0)
All values are means (95% CI).
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DMARDs [26].
Improvement of PROs in patients with RA is of major
clinical relevance. Not only are reduced disability and im-
proved HRQoL important treatment goals in themselves,
but such measures also predict long term outcomes. For
example, disability, measured using HAQ, has been shown
to predict mortality in several studies [4,27,28].
In the survey performed in 2009, patients with RA had
significantly lower scores for physical as well as mental
components of HRQoL compared to the expected based
on normative data. This suggests that although patients
with RA surveyed in 2009 were significantly improved
compared to previous investigations in 1997, 2002 and
2005, there is still a major difference in HRQoL compared
to the general population. Evidently, there is still need for
further improvements in the management of RA.
Influence of gender on various aspects of disease severity
has been described in several studies. One retrospective
review of a community based sample revealed a higher
proportion with erosive disease in male patients, but a
greater number of orthopaedic procedures in women [29].
In studies of the Swedish multi-centre early RA BARFOT
cohort, women had slightly higher disease activity, mea-
sured using the DAS28 score, compared to men already at
baseline [30,31], mainly due to higher numbers of tender
joints and worse rating of general health [31]. The dif-
ference in DAS28 increased over time [31] and was still
present after 8 years of follow-up [32]. However, male
patients had higher CRP at baseline [30] and there wasno difference in baseline radiographic joint damage or
progression of joint damage over time [31], although
other studies have suggested that female gender may
be an independent predictor of radiographic progression
[33]. In the BeST study, a randomized controlled trial of 4
response-driven treatment strategies, female patients were
significantly less likely to achieve drug-free remission
[34]. PROs, including the HAQ, have also been noted
to be worse in female patients compared to males in a
large multinational database [35].
One possible explanation for such differences could be
lower muscle mass in women. However, in our study,
there were major differences in SF-36 scores compared
to the general population for both sexes, with greater
numerical differences for women.
The results of the present study are compatible with
the concept that a higher pain perception in women is part
of the explanation for these findings. This may reflect pat-
terns that are not specific for RA, since chronic widespread
pain is twice as frequent in women as in men in the general
population [36], and female sex may be a predictor of
future chronic widespread pain in individuals with re-
gional pain [37]. On the other hand, the relative impact
of RA on co-morbidity and mortality may be at least as
great in women as in men. In a survey that included
part of the population of the present study, treatment
with TNF inhibitors was associated with a lower mortality
in women, but not in men [28]. These differences are of
major clinical relevance, and the underlying mechanisms
should be further studied.
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community-based register of patients with RA diagnosis
from a well-defined area, with structured assessment using
repeated questionnaires during a period of 11 years.
Limitations include the sample size, which affects the
precision of some of the outcome estimates, the lack of
longitudinal data for analysis of individual cases, and
the lack of available objective measures of disease activity
due to the study design.
Conclusions
In a well-defined population of patients with RA that re-
ceived more aggressive treatment over time, we have dem-
onstrated improvement in patient reported outcomes.
Despite similar treatment, male patients reported better
outcomes and greater improvements over time, especially
for pain and physical function. We suggest that patient
reported outcomes should be reported separately in male
and female patients with RA.
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